Potito R. Scalzulli
San Giovanni Rotondo, 71013, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.
Journal: Cancers
Published: January 08, 2026
Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology.
Journal: Frontiers in oncology
Published: May 12, 2025
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Journal: Cancers
Published: January 21, 2024
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma.
Journal: Annals of hematology
Published: June 21, 2022
Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Journal: British journal of haematology
Published: June 02, 2022
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Journal: Hematological oncology
Published: August 31, 2021
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.
Journal: Therapeutic advances in hematology
Published: April 16, 2021
Log reduction of leukemic cells and minimal residual disease by flow cytometry represent effective predictors of clinical outcome in elderly patients with acute myeloid leukemia.
Journal: Cytometry. Part B, Clinical cytometry
Published: February 21, 2021
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
Journal: European journal of haematology
Published: January 23, 2020
Last Updated: 09/26/2026